Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy

Status: Completed

Protocol number: MA16620

Sponsor: F Hoffman-La Roche Ltd

Company division: Pharmaceutical

Official Scientific Title: A randomized, open-label study of the effect of anemia correction with NeoRecormon on cardiac structure and function in anemic patients with early diabetic nephropathy.

Brief summary: This study will assess the effect of anemia correction with NeoRecormon on cardiac structure and function in patients with early diabetic nephropathy. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals. Target sample size is 160.

Study phase: III

Study type: Interventional; Treatment; Randomized; Open Label; Active; Parallel; Safety/Efficacy study

Condition: Anemia

Intervention type: Drug

Intervention name: epoetin beta[NeoRecormon]

Primary outcome: 1. Efficacy: Left ventricular mass index

Key secondary outcomes: 1. Efficacy: LVESVI, LVEDVI, left ventricular ejection fraction, fractional shortening, % patients with stable hemoglobin levels between 13-15 g/dL. Safety: Adverse events, lab parameters, vital signs.

Inclusion criteria:

  • adult patients >=18 years of age;
  • type 1 or type 2 diabetes;
  • stable glycemic control for >=3 months;
  • diabetic nephropathy.

Exclusion criteria:

  • women who are pregnant, breastfeeding, or unwilling to use a reliable contraceptive method;
  • previous treatment with erythropoietin or other erythropoietic substance;
  • nondiabetic renal disease, nephrotic syndrome;
  • blood transfusion within the 3 months prior to enrollment;
  • administration of any investigational drug within 30 days preceding the study start, and during the study.

Gender: Males or Females

Age limits: Min: 18 Years Max: N/A (No limit)

Accepts healthy volunteers: No

Trial registration date: 05/23/2005

Date last updated: 8/19/2008


Link to trial result

This trial was conducted at the following locations:

Austria

  • Linz

Brazil

  • Sao Paulo

Czech Republic

  • Jihlava
  • Liberec

Denmark

  • København
  • Roskilde

Finland

  • Jyvaeskylae

Germany

  • Heidelberg
  • München

Greece

  • Alexandroupolis
  • Athens
  • Ioannina
  • Nikea
  • Thessaloniki
  • Veria

Hungary

  • Budapest
  • Miskolc
  • Pecs
  • Szombathely

Italy

  • Ancona
  • Cagliari
  • Caserta
  • Cinisello Balsamo
  • Desio
  • Lecco
  • Messina
  • Milano

Mexico

  • Chihuahua
  • Mexico City
  • Monterrey

Poland

  • Bialystok
  • Katowice
  • Radom

Russian Federation

  • Moscow

Singapore

  • Singapore

Spain

  • Barakaldo
  • Barcelona
  • Galdakao
  • La Coruna
  • Madrid
  • Valencia

Sweden

  • Stockholm

Thailand

  • Bangkok
  • Chiang Mai
  • Chonburi

United Kingdom

  • Belfast
  • Cambridge
  • London
  • Middlesborough
  • Salford
  • Sheffield
  • Wrexham

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply